Pharmaceutical - Anti-virals, Financial

Filter

Current filters:

Anti-viralsFinancial

Popular Filters

European Union's response to Ebola emergency

18-11-2014

West Africa is currently facing the largest and most complex Ebola epidemic on record. Guinea, Liberia…

Anti-viralsFinancialPharmaceuticalResearchRest of the WorldTropical diseases

Roche drops rights to Inovio’s prostate cancer candidate

17-11-2014

Swiss pharma major Roche has terminated its 2013 collaboration, option, and license agreement with US…

Anti-viralsFinancialINO-1800INO-5150Inovio PharmaceuticalsLicensingOncologyPharmaceuticalRoche

EFPIA and IMI launch 280 million-euro Ebola program, calling for proposals

EFPIA and IMI launch 280 million-euro Ebola program, calling for proposals

10-11-2014

The European Federation of Pharmaceutical Industries and Associations, its specialized group Vaccines…

Anti-viralsEuropeFinancialPharmaceuticalResearchUSA

CSL buys Novartis’ influenza vaccines business for $275 million

CSL buys Novartis’ influenza vaccines business for $275 million

27-10-2014

Swiss pharma major Novartis has agreed to divest its influenza vaccines business to Australia’s CSL…

Anti-viralsbioCSLCSL LimitedFinancialMergers & AcquisitionsNovartisPharmaceuticalVaccines

IMS Health identifies 10 events that may transform the delivery of health care

IMS Health identifies 10 events that may transform the delivery of health care

23-09-2014

As the global market for drugs surpasses $1 trillion this year, growing payer scrutiny of value for money…

Anti-viralsFinancialGlobalHealthcarePharmaceuticalRegulationResearchVaccines

US court orders SIGA to pay PharmAthene lump sum expectation damages

US court orders SIGA to pay PharmAthene lump sum expectation damages

11-08-2014

USA-based biodefense company PharmAthene says that, on Friday, the Delaware Court of Chancery issued…

Anti-viralsDelaware Court of ChanceryFinancialLegalPharmaceuticalPharmAtheneSIGA TechnologiesTecovirimatUSA

Biota tanks as flu drug candidate disappoints

Biota tanks as flu drug candidate disappoints

04-08-2014

USA-based Biota Pharmaceuticals saw its shares slump 29% to a record low of $2.29 on Friday, after the…

Anti-viralsAntibiotics and Infectious diseasesBiota PharmaceuticalsFinancialPharmaceuticalResearchUSA

Report: US state governments may spend $55 billion on hepatitis C drugs

Report: US state governments may spend $55 billion on hepatitis C drugs

17-07-2014

State legislatures in the USA will need to find billions in their budgets to purchase costly new hepatitis…

Anti-viralsExpress ScriptsFinancialGilead SciencesHealthcarePharmaceuticalSovaldiUSA

Isis Pharma earns $1 million GSK milestone on hepatitis B virus program

Isis Pharma earns $1 million GSK milestone on hepatitis B virus program

03-07-2014

USA-based Isis Pharmaceuticals has earned yet another $1 million payment from UK pharma giant GlaxoSmithKline,…

Anti-viralsFinancialGlaxoSmithKlineIsis PharmaceuticalsPharmaceuticalResearch

AbbVie opens expanded manufacturing facility in Ireland

AbbVie opens expanded manufacturing facility in Ireland

03-06-2014

The chairman and chief of US drugmaker AbbVie, Richard Gonzalez, accompanied by other senior executives,…

AbbVieAnti-viralsFinancialIrelandPharmaceuticalProduction

AbbVie files NDA for oral, interferon-free treatment of hepatitis C

22-04-2014

US drugmaker AbbVie has submitted its New Drug Application to the US Food and Drug Administration for…

AbbVieAnti-viralsEnanta PharmaceuticalsFinancialNorth AmericaPharmaceuticalRegulationUSA

Pharma Summit: AIDS activists picket to demand South African reform

Pharma Summit: AIDS activists picket to demand South African reform

14-03-2014

Delegates at The Economist’s Pharma Summit in London yesterday were greeted by AIDS activists picketing…

Anti-viralsFinancialLegalPharmaceuticalPricingSouth AfricaUK

Catalyst-rich period ahead for key trial results from BioLineRx

09-12-2013

Israeli drug developer BioLineRx is entering a catalyst-rich phase over the next 12 months, which will…

Anti-viralsBioLineRxBL-1040BL-8020BL-8040Cardio-vascularFinancialOncologyPharmaceuticalResearch

DC AIDS protesters join push to demand China gives $1 billion to fight global AIDS

25-10-2013

The Washington DC, USA based AIDS Healthcare Foundation (AHF) is spearheading a series of US and global…

Anti-viralsAsia-PacificFinancialPharmaceuticalPolitics

HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst

20-05-2013

While the risks involved in HIV vaccine development have turned Big Pharma away from pursuing a preventative…

Anti-viralsBiotechnologyFinancialHVTN 505PharmaceuticalResearchVaccines

Specialty drug costs account for over 50% of the total cost of care for RA and hepatitis C patients in USA

03-04-2013

According to two new studies by Prime Therapeutics, a leading US pharmacy benefit manager, rheumatoid…

Anti-Arthritics/RheumaticsAnti-viralsBiotechnologyFinancialHealthcareNorth AmericaPharmaceutical

Australia to subsidize groundbreaking hepatitis C drugs under PBS

19-02-2013

The Australian government said on February 19 that it is extended subsidies of important medicines each…

Anti-viralsAsia-PacificFinancialHealthcareIncivoJohnson & JohnsonMerck & CoPharmaceuticalPricingVictrelis

News briefs: Novartis drops Ruvise MAA; B-MS settlement; Germany donates to Global Fund

25-01-2013

The European Medicines Agency says it has been formally notified by Swiss drug major Novartis (NOVN:…

Anti-viralsBMS-986094Bristol-Myers SquibbFinancialLegalNovartisPharmaceuticalRare diseasesRegulationRuviseTropical diseases

New executive director of the Global Fund outlines ambitious agenda

21-01-2013

Mark Dybul yesterday took charge as executive director of the Global Fund to Fight AIDS, Tuberculosis…

Anti-viralsAntibiotics and Infectious diseasesFinancialManagementPharmaceuticalTropical diseases

New Zealand to fund Gilead's Atripla and Truvada

27-11-2012

New Zealand's Pharmaceutical Management Agency PHARMAC says that, effective December 1, it will fund…

Anti-viralsAsia-PacificAtriplaBiotechnologyFinancialGilead SciencesPharmaceuticalRegulationTruvada

Domestic HIV funding outpaces international investments

19-07-2012

A new report by the Joint United Nations Program on HIV/AIDS (UNAIDS) shows that domestic funding for…

Anti-viralsFinancialGlobalHealthcarePharmaceutical

US House of Representatives trumps Administration on Global AIDS budgets

22-05-2012

The US House of Representatives has budgeted $193 million more to global AIDS programs in the 2013 Foreign…

Anti-viralsFinancialHealthcareNorth AmericaPharmaceuticalPolitics

COMPANY SPOTLIGHT

Parexel

Parexel

Back to top